![PDF) Efficacy and safety of topical halometasone in eczematous dermatoses in Indian population: An open label, noncomparative study PDF) Efficacy and safety of topical halometasone in eczematous dermatoses in Indian population: An open label, noncomparative study](https://i1.rgstatic.net/publication/221843201_Efficacy_and_safety_of_topical_halometasone_in_eczematous_dermatoses_in_Indian_population_An_open_label_noncomparative_study/links/09e414fa2242b89e00000000/largepreview.png)
PDF) Efficacy and safety of topical halometasone in eczematous dermatoses in Indian population: An open label, noncomparative study
![Topical corticosteroids for atopic eczema: clinical and cost effectiveness of once‐daily vs. more frequent use - Green - 2005 - British Journal of Dermatology - Wiley Online Library Topical corticosteroids for atopic eczema: clinical and cost effectiveness of once‐daily vs. more frequent use - Green - 2005 - British Journal of Dermatology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/0d32899b-8b2e-4dbf-bfbe-47d092f8879c/bjd_6410_f2.gif)
Topical corticosteroids for atopic eczema: clinical and cost effectiveness of once‐daily vs. more frequent use - Green - 2005 - British Journal of Dermatology - Wiley Online Library
![PDF) Technology assessment report commissioned by the HTA Programme on behalf of The National Institute for Clinical Excellence Clinical and cost-effectiveness of once daily versus more frequent use of same potency topical PDF) Technology assessment report commissioned by the HTA Programme on behalf of The National Institute for Clinical Excellence Clinical and cost-effectiveness of once daily versus more frequent use of same potency topical](https://0.academia-photos.com/attachment_thumbnails/33706003/mini_magick20190330-20963-rlom3q.png?1553945720)
PDF) Technology assessment report commissioned by the HTA Programme on behalf of The National Institute for Clinical Excellence Clinical and cost-effectiveness of once daily versus more frequent use of same potency topical
BIOAVAILABILITY AND ACTIVITY OF 0.1% AMCINONIDE PREPARATIONS: COMPARISON WITH PROPRIETARY TOPICAL CORTICOSTEROID FORMULATIONS OF
![PDF) Formulation factors affecting the isomerization rate of betamethasone-17-valerate in a developmental hydrophilic cream - a HPLC and microscopy based stability study PDF) Formulation factors affecting the isomerization rate of betamethasone-17-valerate in a developmental hydrophilic cream - a HPLC and microscopy based stability study](https://i1.rgstatic.net/publication/295251264_Formulation_factors_affecting_the_isomerization_rate_of_betamethasone-17-valerate_in_a_developmental_hydrophilic_cream_-_a_HPLC_and_microscopy_based_stability_study/links/59d1292a0f7e9b4fd7fa2470/largepreview.png)